N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease  by Jarai, Rudolf et al.
LN
i
N
S
T
p
i
c
h
o
l
t
t
e
p
t
g
F
d
N
b
d
m
w
(
s
t
i
i
n
e
f
N
w
T
o
q
C
t
r
(
J
w
t
t
c
2
p
s
Journal of the American College of Cardiology Vol. 44, No. 9, 2004
© 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00
Published by Elsevier Inc.ETTERS TO THE EDITOR
N
h
n
r
w
(
a
w
t
m
e
e
a
c
b
e
R
R
K
3
W
M
A
A
E
R
1
2
3
4
5
6
7
8-Terminal Pro-Brain Natriuretic Peptide
n Relation to Inflammation, Myocardial
ecrosis, and the Effect of an Invasive
trategy in Unstable Coronary Artery Disease
he strong prognostic significance of B-type natriuretic
eptide (BNP) and its N-terminal fragment (Nt-proBNP)
n unstable coronary artery disease (UCAD) has been
onfirmed by several recent studies (1–6). Little is known,
owever, about the impact of early invasive strategies on
utcome of patients with UCAD and elevated Nt-proBNP
evels. No data are available from randomized prospective
rials investigating the role of early coronary revasculariza-
ion with respect to elevated Nt-proBNP levels. Data exist
xclusively from retrospective analyses. Because a good
redictor of outcome would influence routine clinical prac-
ice by selecting appropriate treatment, we have read with
reat interest the important results from the Fragmin and
ast Revascularization during Instability in coronary artery
isease (FRISC) II trial by Jernberg et al. (7).
These investigators demonstrated for the first time that
t-proBNP could help to identify patients who would
enefit from an early coronary intervention within seven
ays after randomization. The favorable effect of invasive
anagement was most apparent when Nt-proBNP levels
ere in the third tertile (1,345 ng/l) and interleukin
IL)-6 levels exceeded 5 ng/l (7). Furthermore, it was also
hown that Nt-proBNP was independently associated with
wo-year mortality (but not with subsequent myocardial
nfarction [MI]) among patients randomized to the
nvasive-strategy arm as well as among patients within the
oninvasive treatment group. Moreover, left ventricular
jection fraction, determined by echocardiography two to
our days after admission, did not affect the association of
t-proBNP with mortality (7).
With respect to other clinical investigations (1,6,8), we
ould emphasize looking at the data in a different way:
hese trials demonstrated an inhomogeneous distribution
f mortality along the BNP/Nt-proBNP levels in the upper
uartile. In the Global Use of Strategies To Open Occluded
oronary Arteries (GUSTO) IV trial (early revasculariza-
ion 2%), Nt-proBNP levels were measured 9.5 h after
andomization by use of the same sandwich immunoassay
Elecsys 2010, Roche Diagnostics, Sweden) as used by
ernberg et al. (6,7). In contrast, Nt-proBNP plasma levels
ere determined 39 h after randomization in the FRISC-II
rial. Despite this difference in the timing of blood collec-
ion, the quartiles of the Nt-proBNP levels exhibited similar
ut-off values in both trials (25th percentile: 237 ng/l and
83 ng/l; 50th percentile: 669 ng/l and 672 ng/l; 75th
ercentile: 1,869 ng/l and 1,820 ng/l, respectively) and also
howed similar exponential relation to follow-up mortality.In the GUSTO-IV trial the mortality rate above the 90th
t-proBNP percentile (4,634 ng/l) was substantially
igher than the mortality rate between the 80th (2,399
g/l) and 90th (4,634 ng/l) percentile (27% vs. 15%;
espectively; p  0.0001). The mortality in this latter group
as also significantly higher than in the previous decile
15% vs. 10.5%; p  0.0001). Moreover, more than 30% of
ll deaths in the GUSTO-IV trial occurred among patients
ith Nt-proBNP levels above the 90th percentile, and more
han 50% occurred above the 80th percentile (6).
A different analysis of the data provided by FRISC-II
ight demonstrate whether patients with Nt-proBNP lev-
ls above the 80th and 90th percentile would benefit from
arly revascularization. Conversely, owing to the missing
ssociation between Nt-proBNP and consecutive MI, it
annot be excluded that this highest risk group has a less
eneficial effect from early coronary revascularization, as
xpected.
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